Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005800 · ClinicalTrials.gov registry record · Phase 2
Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00005800 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 45 participants.
The verdict
NCT00005800, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel in treating women who have stage III breast cancer.
Interventions
- DRUG Docetaxel
- DRUG Doxorubicin
- BIOLOGICAL Filgrastim
- PROCEDURE Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 1999-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005800
The ClinicalTrials.gov registry entry for NCT00005800 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT00005800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005800 about?
NCT00005800 is a clinical study titled "Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of doxorubicin and docetaxel in treating women who have stage III breast...
What is the current status of trial NCT00005800?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 1999-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00005800?
The interventions under investigation include: Docetaxel (DRUG), Doxorubicin (DRUG), Filgrastim (BIOLOGICAL), Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00005800?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.